Key points are not available for this paper at this time.
The pharmaceutical industry is widely recognized as a crucial sector that contributes significantly to the country's economic growth, and the importance of Competition Law in this industry is widely acknowledged. However, this market is also susceptible to various unlawful transactions and monopolistic competition, given that medicine is an essential item that every consumer needs, and market players often take advantage of this to trade their products and achieve monopolies or control product prices. To address these issues, the Competition Act, 2002 was instituted, and various regulations were implemented to regulate market competition across different sectors. The importance of public health is a major consideration in the pharmaceutical industry, and it is crucial to understand how competition law is applied in this sector. This article aims to shed light on the interplay between IP rights and competition law in the pharmaceutical sector and provide insight into how the development of the industry has spurred competition in the market. Additionally, the article will offer some suggestions.
Sahai et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: